A new comprehensive review from researchers at the Icahn School of Medicine at Mount Sinai details how decades of cancer vaccine research are converging into a new era of more precise, personalized, ...

Researchers from the Wilmer Eye Institute, Johns Hopkins Medicine Center for Nanomedicine - which designs nanotechnology-based platforms for clinical translation across specialties - developed a ...

YieldMax MRNA Option Income Strategy ETF's distributions have increased alongside MRNA's share price resurgence. See more on MRNY ETF here.

Melanoma, known for its aggressiveness and high mutational burden, presents itself as a prime candidate for neoantigen-targeted immunotherapies. Although ...

Wall Street was given respite from tariff turmoil as Trump announced he was backing away from the Greenland acquisition.

The University of Auckland is hosting the research as part of the Global COVID Vaccine Safety (GCoVS) Project. Scientists ...

How do immune cells strike a balance, unleashing rapid attacks against pathogens or cancer, while avoiding damage to healthy cells? Research into an immune kill switch holds potential for controlling ...

The latest Public Health Alerts report details influenza activity, vaccination rates, and flu-related deaths last season in ...

CEO Stéphane Bancel said on Thursday that his company will not fund further late-stage development of vaccines as the U.S.

The company plans to begin enrolling the trial next quarter across eight US sites to test the vaccine as a monotherapy and in combination with Keytruda.

Moderna does not plan to ‌invest in new late-stage vaccine trials because of growing opposition to immunizations from U.S.